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Dear Editor, 
The patient is a 27-year-old, woman, who was diagnosed 
with dependence of cocaine as a teenager. She has a history 
of multiple admissions for clinical treatment and subsequent 
partial response to antipsychotic medication. Over time, she has 
been prescribed haloperidol and risperidone. The side effects 
included lethargy.
On admission, she was expressing rapid discourse, mainly 
of a persecutory nature. She was started on olanzapine at 
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a dose of 2.5 mg daily, which was increased to 7.5 mg on 
day 7 and to 10 mg on day 14 (an oral dose administered 
at night). Her psychotic symptoms did not persist. Routine 
physical examination and investigations were all within normal 
limits including liver enzymes. After 6 weeks of a dose of 
10 mg/day, her dependence symptoms had returned to their 
pre-morbid levels.1
The neuropharmacological profile of the atypical antipsychotic 
olanzapine is consistent with a potentially useful medication for 
cocaine abuse, confirming the hypothesis that patients treated 
with olanzapine have reduced cocaine craving and abuse. 
The US FDA has approved a limited number of treatments 
for alcohol, nicotine and opioid dependence; however, no 
treatments for other abused drugs such as marijuana, cocaine 
or methamphetamine are approved.1 Because cocaine delivers a 
particularly positive and reinforcing high, most users do not seek 
treatment voluntarily until the behavioral patterns have resulted 
in significant impairment in function or health problems. Craving 
for cocaine is often so intense that an individual needs to be 
initially entered into residential treatment in order to establish 
abstinence from the drug. Treatment must be multimodal, 
including medical, psychological, and social strategies to help 
the patient establish and maintain abstinence.2
The history of hypersensitivity to olanzapine in this patient 
was exclusio, included experiences of psychotic in this patients
dementia and the use of other psychotropic medications. Baseline 
laboratory testing included a chemistry screen, complete blood 
count, and urinalysis. The patient received urinary pregnancy 
testing prior to starting medications, and at monthly intervals 
throughout the study.3
As a dopamine antagonist, olanzapine may worsen this 
hedonic deregulation and this may have made it difficult for 
olanzapine-treated subjects to remain abstinent.  
Risperidone was found to be effective in reducing craving 
and relapse among cocaine-dependent schizophrenics in an 
open trial.2
Olanzapine was well tolerated. The adverse events reported 
included: weight gain (40%), drowsiness (40%), constipation 
(13%), dizziness (10%), dry mouth (7%), nausea (7%), 
restlessness (7%) and urticaria (3%). But in this case, there 
were not any of these events. The history of hypersensitivity to 
olanzapine in this patient was exclusion.4
Fur ther studies to clari fy this point and the precise 
pharmacology effect would be helpful. Olanzapine may be 
superior to traditional neuroleptics for the treatment of cocaine 
dependence due to its less severe side effect profile.5 This case 
was intended to determine if olanzapine showed any promise 
for the treatment of cocaine dependence. Further controlled 
research is warranted to more precisely determine the effect of 
olanzapine in this case.
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Mediante o exposto, podemos constatar que pesquisas que 
examinem resultados das crianças com HAF, considerando 
também concomitante à HVD, avaliando-se os efeitos da história 
de álcool mediados pela história de violência ou vice-versa, 
mostram-se de extrema relevância.  
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